Close Menu

NEW YORK ─ The COVID-19 crisis has slowed Quest Diagnostics' lab acquisition efforts, but the firm believes that industry consolidation will continue apace once the pandemic is over.

Various factors could counter the company's consolidation opportunities, including the revenues labs have garnered from COVID-19 testing, the significant expansion of molecular testing at many hospital labs over the course of the last year, and the pause in cuts under the Protecting Access to Medicare Act (PAMA).

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.